Rilonacept (arcalyst) 220MG/VIL INJ
Ended Awarded Last action
- Contract number
- 36C26023F0351
- Awardee
-
Kiniksa Pharmaceuticals (Uk), LTD. UEI HBHWNLNMHSV5
- Awarding agency
-
Veterans Integrated Service Network 20
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $170,125
Award facts
- Contract value 100% obligated
- $170,125.09 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Seattle, WA 98108, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | -$26,201 | |
| Original award | $196,326 |
About this award
Kiniksa Pharmaceuticals (UK), LTD. was awarded a $170,125.09 firm fixed-price delivery order by the Department of Veterans Affairs Veterans Integrated Service Network 20 on June 1, 2023, with a completion date of May 31, 2024. The contract covers the supply of Rilonacept (Arcalyst) 220mg/vial injectable medication, a therapeutic agent used to treat chronic inflammatory disorders including recurrent pericarditis and cryopyrin-associated periodic syndromes. The delivery order was issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), with the place of performance in Seattle, Washington. No set-aside designation was applied to this award, indicating open competition in the procurement process.
This delivery order is supported by Kiniksa Pharmaceuticals' existing indefinite-delivery vehicles with the VA, including a $5.9 million single-award Blanket Purchase Agreement with the VA National Acquisition Center valid through November 2025. As a UK-registered biopharmaceutical company specializing in innovative anti-inflammatory therapies, Kiniksa has become a primary supplier of Arcalyst to federal healthcare programs serving veterans and other federal beneficiaries across multiple Veterans Integrated Service Networks and Department of Justice facilities. The delivery order represents part of the company's ongoing commitment to provide critical pharmaceutical products to support the healthcare mission of the Veterans Health Administration.
Quick answers
Who was awarded contract 36C26023F0351?
36C26023F0351 was awarded to Kiniksa Pharmaceuticals (Uk), LTD. by Veterans Integrated Service Network 20 (Veterans Health Administration) on June 1, 2023.
How much is contract 36C26023F0351 worth?
The government has obligated $170,125 on 36C26023F0351.
Is contract 36C26023F0351 an order under another contract?
Yes. 36C26023F0351 is a delivery order under 36F79722D0002, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C26023F0351 competed?
The extent of competition for 36C26023F0351 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award